Blue sharks might actually be some of nature's most unexpected chameleons
Blue sharks have become very well known for the color of their skin, but new research indicates that these iconic sharks might be more than meets the eye. In fact, blue sharks might just be one of nature's best chameleons, as new data suggests the components responsible for the shark's coloring could allow it to change colors based on its environment.
The research comes from a group of marine biologists who shared their findings at the most recent Society for Experimental Biology Annual Conference in Belgium. The researchers say they discovered these findings while more closely inspecting the small tooth-like scales that are responsible for the blue coloring of the sharks.
Today's Top Deals
XGIMI Prime Day deals feature the new MoGo 4 and up to 42% off smart projectors
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
These tooth-like scales are known as dermal denticles. When looking at them more closely, the researchers found that the scales feature small pulp cavities that contain guanine crystals. These crystals are responsible for the camouflage ability found in chameleons, which suggests that blue sharks may be able to use similar color-changing abilities to hide in different environments.
The belief is that these color-changing crystals allow the sharks to blend in with the darker waters of the deep. For example, the researchers suggest that the cells could become more tightly packed together as the pressure increases on the shark's body, thus making the creature's skin much darker when it dives deeper.
So far, the researchers have only simulated the possible chances of what might happen when the pressure is increased on the cells. From here, the researchers want to take their findings and try to translate them to the real world by investigating the blue shark's chameleon ability in greater depth. The hope is that they'll be able to prove that the sharks change their color based on their environment, even if that just means they get darker when diving deeper.
There's a lot we still don't know about sharks, including why some sharks freeze when turned upside down. But, hopefully, future research like this can help us uncover more about these majestic and terrifying creatures.
More Top Deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
See the
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions
COPENHAGEN, Denmark, July 15, 2025--(BUSINESS WIRE)--A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune diseases. The findings reaffirm the safety of Denmark's childhood vaccination program. An extensive new Danish register-based study - the largest of its kind - supports the safety of the national childhood immunization program. Analyzing data from over 1 million children, the study found no increased risk of autism, asthma, or autoimmune diseases in vaccinated children. "Our results are reassuring. By analyzing data from more than one million Danish children, we found absolutely no indication that the very small amount of aluminum used in the childhood vaccination program increases the risk of 50 different health outcomes during childhood," says Anders Hviid, Head of Department at Statens Serum Institut (SSI) and principal investigator on the study. Aluminum, used as an adjuvant to enhance the immune response, has been a component in some vaccines since the 1930s. Researchers from SSI used Denmark's unique national health registers to follow children born between 1997 and 2018, investigating the associations between aluminum-containing vaccines and a total of 50 health outcomes - including asthma, allergies, autoimmune conditions, and neurodevelopmental disorders. "This is the first study of this scale and with such comprehensive analyses, and it confirms the strong safety profile of the vaccines we've used for decades in Denmark," says Anders Hviid. The results are being published at a time of heightened international debate about vaccine safety which makes the Danish study highly relevant. "In an era marked by widespread misinformation about vaccines, it is crucial to rely on solid scientific evidence. Large, population-based register studies like this one - tracking more than a million children over many years - are a bulwark against the politicization of health science which undermines public trust in vaccines. It is absolutely essential to distinguish real science from politically motivated campaigns - otherwise, it is the children who will end up paying the price," says Anders Hviid. Reference: Andersson NW, Bech Svalgaard I, Hoffmann SS, et al. Aluminum-adsorbed vaccines and chronic diseases in childhood. A nationwide cohort study. Ann Intern Med. 15 July 2025. [Epub ahead of print]. doi:10.7326/ANNALS-25-00997 Fact Box: Researchers from Statens Serum Institut (SSI) used Denmark's unique health registers to analyze data from more than 1 million Danish children born between 1997 and 2018 to investigate potential long-term health effects of aluminum-containing vaccines. The study examined 50 different conditions and found no statistical association between aluminum content in vaccines and increased risk of developing autism, autoimmune diseases, asthma, or allergic conditions such as hay fever and food allergies. The study has just been published in the prestigious medical journal Annals of Internal Statens Serum Institut (SSI) View source version on Contacts Anders Hviid, aii@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CBS News
4 hours ago
- CBS News
Largest-ever merger of black holes forms one 225 times the mass of the sun, astronomers say
Scientists say they detected the largest-ever merger of two black holes, forming one that is 225 times the mass of the sun, adding that the new discovery "pushes the limits of" how astronomers understand how black holes are created. Two black holes combined to make the massive one, according to the LIGO-Virgo-KAGRA Collaboration, an international group that uses gravitational waves to detect black hole mergers and who identified the event. Gravitational waves occur when there are minute distortions in spacetime, caused by events like black hole mergers, the group said in a news release. One of the black holes was about 103 times the mass of the sun. The other was about 137 times it. These large black holes may have been formed by even earlier mergers, Professor Mark Hannam, from Cardiff University and a member of the LIGO Scientific Collaboration, said in a news release. Even within the merger, the black holes are rapidly spinning, scientists said. Their rotation speed is about 400,000 Earth's rotation speed, the collaboration said in a graphic. They are moving at about 80% to 90% of the maximum possible speed. "The black holes appear to be spinning very rapidly — near the limit allowed by Einstein's theory of general relativity," said Dr. Charlie Hoy, a gravitational-wave astrophysicist, LIGO member and postdoctoral research fellow at the University of Portsmouth, in the news release. "That makes the signal difficult to model and interpret." The massive black hole has been dubbed GW231123. Its unusual size and behavior is challenging scientists' understanding of black hole formation, Hannam said. Previously, the largest known black hole that came from a merger was about 140 times the mass of the sun. GW231123's discovery is also opening doors for new avenues of research, astronomers said. The behavior and size of the black hole "pushes the limits of" current theoretical models and existing gravitational-wave detection technology, the LIGO-Virgo-KAGRA Collaboration said. "It will take years for the community to fully unravel this intricate signal pattern and all its implications," Dr. Gregorio Carullo, a LIGO member and an assistant professor at the University of Birmingham's Institute for Gravitational Wave Astronomy, said in a statement. "Despite the most likely explanation remaining a black hole merger, more complex scenarios could be the key to deciphering its unexpected features. Exciting times ahead!" The black hole was discovered in November 2023, during an observation period by the LIGO-Virgo-KAGRA Collaboration. The observation period began in May 2023, and the first part of the period ended in January 2024. More information about GW231123 and other black holes discovered by the collaboration will be presented this month at the 24th International Conference on General Relativity and Gravitation (GR24) and the 16th Edoardo Amaldi Conference on Gravitational Waves, two conferences presented jointly in Glasgow, Scotland. Data from the observation window will be published later in the summer. The data used to detect and study the massive black hole will also be made available for other researchers to use, the collaboration said.
Medscape
6 hours ago
- Medscape
Multiomics Platform May Guide Melanoma Treatment
TOPLINE: The novel Tumor Profiler (TuPro) project, which analyzed melanoma samples using nine independent technologies, demonstrated feasibility in guiding treatment decisions. Molecular tumor board recommendations on the basis of TuPro were deemed useful in 75% of cases. METHODOLOGY: Despite advances in melanoma therapy, many patients experience relapse and lack effective treatment options. Multiomics and single-cell profiling promise comprehensive tumor insights but require evaluation for feasibility and clinical utility in guiding treatment decisions. Researchers conducted a prospective, multicentric observational project (TuPro) enrolling 116 patients with any subtype of melanoma, from whom 126 biopsy samples were collected at three Swiss hospitals from January 2019 to November 2020. The TuPro application cohort included 93 patients (103 biopsy samples). The biopsies were analyzed using nine independent technologies, including single-cell genomics, transcriptomics (single-cell RNA sequencing [scRNA-seq]), targeted proteomics (imaging mass cytometry [IMC]), drug phenotyping (Pharmacoscopy), and digital pathology, which generated up to 500 Gb of data per sample within a 4-week turnaround time. The molecular tumor board evaluated data from all technologies to inform treatment recommendations across three patient groups: adjuvant setting (n = 13), palliative standard of care (n = 45), and palliative beyond standard of care (n = 37). The median follow-up duration was 20.5 months. TAKEAWAY: Patients in the palliative standard-of-care group achieved an objective response rate of 60% and a disease control rate of 62%, whereas those in the palliative beyond standard-of-care group achieved an objective response rate of 38% and a disease control rate of 54%. In a matched analysis of patients who received at least three treatment lines, the median progression-free survival reached 8.34 months in the TuPro cohort vs 2.0 months in the non-TuPro cohort (adjusted hazard ratio, 0.23; 95% CI, 0.07-0.79; adjusted P = .0201), suggesting benefit in heavily pretreated patients. Molecular data from TuPro were considered useful by the multidisciplinary molecular tumor board in 75% of evaluated cases, representing a 39% and 33% increase in concordance vs standard clinical workup alone (diagnostic levels 1 and 2, respectively). The TuPro workflow led to actual therapies in 87% of cases. A minimal set of four technologies (next-generation DNA sequencing [NGS], IMC, Pharmacoscopy, and scRNA-seq) could cover all 54 markers used for treatment decision-making at 1.15-fold higher costs than those for the standard NGS for adjuvant or palliative standard-of-care settings and 1.8-fold higher costs than those for the palliative beyond standard-of-care setting. IN PRACTICE: 'This study demonstrates the feasibility of using advanced multiomics approaches, including spatial proteomics, to guide therapy decisions in late-stage melanoma — one of the most aggressive and treatment-resistant cancers — with a reproducible patient benefit,' said Stéphane Chevrier, PhD, CSO, and cofounder of Navignostics and contributor to the TuPro study, in a press release. 'This is a major step toward pan-cancer diagnostics. By providing a comprehensive view of the tumor biology, the approach could eventually identify features that are predictive for treatments across cancer indications.' SOURCE: The study, led by Nicola Miglino, the University of Zurich and University Hospital, Zurich, Switzerland, was published online in Nature Medicine. LIMITATIONS: The current approach of selecting markers for treatment decisions by human experts did not capture all potentially relevant information. The retrospective comparison between TuPro and non-TuPro cohorts limited extrapolation and generalizability of the results. Additionally, definitive conclusions about the clinical value of serial sampling cannot be drawn owing to heterogeneous results and a small sample size. DISCLOSURES: The study received an open-access funding from the University of Zurich. Several authors reported having advisory roles or receiving research funding and having other ties with various pharmaceutical companies. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
